IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Comprehensive Review Article on Medicinal Uses, Phytochemistry, Pharmacological Activities, and Pharmaceutical Significance of Rhapis excelsa (Lady plam)

Ms. P. S. GAIKWAD*, Dr. L. M. PURANE, Mr. P. P. KAMBLE, Ms. M. G. GUJARE

Yashoda Technical Campus, Faculty of Pharmacy Satara

Abstract: Rhapis excelsa (Thunb.) Henry ex Rehder, commonly known as the Lady Palm or Broadleaf Lady Palm, is a slow-growing, multi-stemmed ornamental palm of the family Arecaceae, native to southern China and Taiwan. Although best known as a decorative indoor and landscape plant, mounting evidence from ethnobotanical surveys, phytochemical analyses, and in vitro pharmacological studies reveals a range of biologically active constituents and therapeutically relevant activities across multiple plant parts — including the leaves, roots, rhizomes, seeds, and stem fibres. Bioactive classes documented in the genus Rhapis and closely related Arecaceae members include flavonoids, phenolic acids, sterols (notably beta-sitosterol), triterpenoids, fatty acids, and polysaccharides. Reported pharmacological activities encompass antioxidant, anti-inflammatory, antimicrobial, antidiabetic, hepatoprotective, and immunomodulatory effects. The palm also demonstrates outstanding efficacy as a phytoremediation agent for indoor volatile organic compounds (VOCs), with relevance to respiratory health. Traditional medicine systems in China and Southeast Asia have employed various Rhapis preparations for wound healing, fever management, urinary complaints, and tonic purposes. This review consolidates and critically evaluates available phytochemical, pharmacognostic, and pharmacological data on Rhapis excelsa, identifies gaps in current knowledge, and outlines future research directions of pharmaceutical relevance.

Keywords: Rhapis excelsa, Lady Palm, Arecaceae, pharmacognosy, phytochemistry, flavonoids, beta-sitosterol, antioxidant, anti-inflammatory, phytoremediation, herbal medicine, natural products.

Introduction The family Arecaceae (Palmae), comprising over 2,600 species across approximately 181 genera, is one of the most economically and medicinally significant plant families in the world. It provides food (dates, coconut, sago, palm oil), construction materials, fibres, waxes, and a broad spectrum of traditional medicines used by cultures across tropical and subtropical regions globally. Within this family, the genus Rhapis — comprising approximately 12 species of small, clumping, shade-tolerant palms native to East and Southeast Asia — has received relatively little systematic pharmacological attention compared to commercially dominant palms such as Cocos nucifera, Elaeis guineensis, or Phoenix dactylifera.

Rhapis excelsa, the most widely cultivated species in the genus, has been maintained as an ornamental plant in China and Japan for several centuries, and its ethnomedicinal applications — while documented in traditional Chinese medicine (TCM) texts and folk medicine compendiums — have not been comprehensively investigated through modern pharmacological and clinical research frameworks. This represents both a significant knowledge gap and a research opportunity of considerable pharmaceutical interest.

The renaissance of interest in plant-derived medicines, driven by global concerns about antimicrobial resistance, side effects of synthetic pharmaceuticals, and the growing market for botanical nutraceuticals and cosmeceuticals, makes a systematic review of Rhapis excelsa's medicinal properties both timely and relevant.

This article presents the first comprehensive review specifically focused on the medicinal, phytochemical, and pharmacological aspects of Rhapis excelsa for the benefit of pharmacy students, researchers, and practitioners in natural product drug discovery.

2. Botanical Identity and Pharmacognostic Description

2.1 Taxonomic Classification

Taxonomic Rank	Classification
Kingdom	Plantae (Angiosperms, Monocots)
Order	Arecales
Family	Arecaceae (Palmae)
Subfamily	Coryphoideae
Tribe	Rhapideae
Genus	Rhapis L.f. ex Aiton
Species	Rhapis excelsa (Thunb.) Henry ex Rehder
Synonyms	Chamaerops excelsa Thunb.; Rhapis flabelliformis L'Her.
Common Names	Lady Palm, Broadleaf Lady Palm, Bamboo Palm (Eng.); Shuro-chiku (Jpn.); Zong Zhu (Chin.)

2.2 Pharmacognostic Macroscopy

The plant forms dense clumps of slender, erect stems (canes) covered with persistent brown fibrous leaf sheaths. Canes reach 1.5–3 m in cultivation, rarely to 4 m outdoors. Leaves are palmate (fan-shaped), deeply divided into 4–10 stiff, glossy, dark-green segments, 20–50 cm wide. Flowers are dioecious, cream-coloured, and produced in branched paniculate inflorescences. Fruits are small (approx. 1 cm), fleshy, white-to-yellow berries, each containing one seed.

2.3 Pharmacognostic Microscopy — Key Features

- Epidermis: Thick cuticle on adaxial leaf surface; stomata confined to abaxial surface (hypostomatic); subsidiary cells paracytic.
- Mesophyll: Compact palisade parenchyma; spongy mesophyll with large intercellular air spaces; abundant raphide-containing idioblasts (calcium oxalate crystals — of diagnostic significance).
- Vascular bundles: Collateral, scattered throughout the mesophyll; surrounded by fibrous bundle sheaths — characteristic of monocotyledons.
- Stem fibres: Sclerenchymatous fibres in the leaf sheath are thick-walled, lignified, and of potential relevance for wound-dressing biomaterial applications.
- Starch grains: Simple, small, and spherical in the root cortex parenchyma.
- Trichomes: Absent; smooth cuticle.

3. Ethnobotanical and Traditional Medicinal Uses

Traditional medicinal applications of Rhapis excelsa span several East and Southeast Asian medicine systems. The plant's documentation in classical Chinese materia medica texts — though less prominent than palms such as Caryota, Livistona, or Phoenix — provides important ethnobotanical starting points for modern pharmacological investigation.

Plant Part Used	Traditional System	Reported Medicinal Use	Mode of Preparation
Root / Rhizome	TCM, Folk (S. China)	Haemostasis, uterine bleeding, menorrhagia	Decoction; charred root ash
Leaf	Folk (Taiwan, SE Asia)	Wound healing, fever reduction, anti-inflammatory poultice	Crushed fresh leaf applied topically; leaf decoction taken orally
Stem fibre (sheath)	Traditional (China, Japan)	Wound dressing, styptic (haemostatic), bandage material	Dried and applied directly to wounds
Seed	TCM adjunct	Tonic, nutritive supplement	Ground into paste; taken with water
Whole plant (aerial)	Folk (Indochina)	Urinary tract complaints, diuretic	Aqueous decoction
Leaf extract	Contemporary herbal	Antioxidant supplement, adaptogenic tonic	Standardised extract in capsule/tablet

The haemostatic use of charred root preparations is particularly consistent with the documented presence of tannins and polyphenolic compounds, which exert astringent and vasoconstriction-promoting effects on mucous membranes and wound surfaces. The use of fibrous stem sheaths as wound dressings aligns with current biomaterial research interest in palm fibre scaffolds for tissue engineering.

4. Phytochemical Constituents

Systematic phytochemical screening of Rhapis excelsa and closely related Rhapis species has identified multiple classes of secondary metabolites. Data from studies on R. excelsa, R. humilis, and broader Arecaceae phytochemical surveys are consolidated below. Pharmaceutical researchers should note that targeted isolation studies on R. excelsa are still limited, and considerable characterisation work remains to be done.

4.1 Phenolic Compounds and Flavonoids

Phenolic compounds constitute one of the most pharmacologically relevant phytochemical classes in Rhapis. Leaf and root extracts have yielded positive Folin-Ciocalteu assays indicating significant total phenolic content. Identified or inferred compounds include:

- Quercetin and quercetin glycosides (quercetin-3-O-glucoside, rutin): Potent antioxidant and anti-inflammatory flavonols widely distributed in Arecaceae; documented by HPLC-DAD analysis in related Rhapis species.
- Kaempferol and kaempferol glycosides: Anti-inflammatory and antioxidant flavonols; detected in leaf extracts of related palm species of subfamily Coryphoideae.
- Luteolin: A flavone with well-documented anti-inflammatory, anticancer, and antiviral activities; reported in Arecaceae leaves.
- Apigenin: Flavone with anxiolytic and anti-inflammatory properties; documented in palm leaf fractions.
- Chlorogenic acid and caffeic acid: Hydroxycinnamic acid derivatives with antioxidant, antidiabetic, and hepatoprotective properties.

- Protocatechuic acid, gallic acid: Hydroxybenzoic acids with antimicrobial and antioxidant activity.
- Ellagic acid: Polyphenolic compound with demonstrated antimutagenic and anticarcinogenic properties.

4.2 Phytosterols

Beta-sitosterol is the most pharmaceutically significant phytosterol documented across Arecaceae, including in Rhapis. It is well-established in the management of benign prostatic hyperplasia (BPH) and as a cholesterol-lowering agent. Stigmasterol and campesterol have also been reported in Arecaceae fractions and are likely present in R. excelsa. Phytosterol-enriched extracts from palm species show promise as functional food ingredients and as raw material for pharmaceutical sterol synthesis.

4.3 Triterpenoids and Saponins

Triterpenoids including ursolic acid, oleanolic acid, and betulinic acid have been identified in leaf waxes and root fractions of several Arecaceae genera. These compounds are of significant pharmaceutical interest: ursolic acid has demonstrated anti-inflammatory, antitumour, and hepatoprotective activities in multiple preclinical models; betulinic acid exhibits selective cytotoxicity against melanoma and other cancer cell lines. Saponins — documented in palm roots and seeds broadly — are relevant to pharmaceutical emulsification, adjuvant formulation, and potential antihyperlipidaemic activity.

4.4 Polysaccharides

Structural and storage polysaccharides extracted from palm stem and seed endosperm include mannans, glucomannans, and glucans. Polysaccharides from related Arecaceae species have demonstrated immunomodulatory activity in macrophage stimulation assays. Palm seed polysaccharides have been investigated as excipient matrices in sustained-release drug delivery systems due to their favourable gelation and swelling properties.

4.5 Fatty Acids and Lipid Fractions

Seed kernel oil from Arecaceae species is typically rich in medium-chain saturated fatty acids (lauric acid, myristic acid) and monounsaturated fatty acids (oleic acid). In Rhapis seeds, oleic acid and linoleic acid are likely predominant. Lauric acid is of direct pharmaceutical relevance as an antimicrobial agent (effective against Gram-positive bacteria and lipid-enveloped viruses) and as a raw material for surfactant synthesis.

4.6 Alkaloids

Low levels of indole and isoquinoline alkaloids have been reported in some Arecaceae leaf extracts. In Rhapis, alkaloid content is not well characterised. The presence of alkaloids should be considered in safety profiling for pharmaceutical use.

4.7 Volatile Organic Constituents (Essential Oil Fraction)

GC-MS analysis of volatile fractions from Rhapis leaf and root material in related genera has identified monoterpenes (alpha-pinene, limonene), sesquiterpenes (beta-caryophyllene), and long-chain alkanes. Beta-caryophyllene is of pharmacological relevance as a selective CB2 receptor agonist with anti-inflammatory properties, approved as a food flavouring substance.

Phytochemical Class	Key Compounds	Plant Part	Pharmacological Relevance
Flavonoids	Quercetin, Kaempferol, Luteolin, Apigenin	Leaf, Root	Antioxidant, Anti-inflammatory, Anticancer
Phenolic acids	Chlorogenic acid, Gallic acid, Ellagic acid	Leaf, Bark	Antioxidant, Antidiabetic, Hepatoprotective
Phytosterols	beta-Sitosterol, Stigmasterol	Seed, Root	Anti-BPH, Cholesterol-lowering

Phytochemical Class	Key Compounds	Plant Part	Pharmacological Relevance
Triterpenoids	Ursolic acid, Betulinic acid, Oleanolic acid	Leaf wax, Root	Anti-inflammatory, Antitumour, Hepatoprotective
Polysaccharides	Mannans, Glucomannans	Stem, Seed	Immunomodulatory, Drug delivery excipient
Fatty acids	Oleic acid, Linoleic acid, Lauric acid	Seed oil	Antimicrobial, Surfactant precursor
Volatile terpenes	beta-Caryophyllene, Limonene	Leaf, Root	Anti-inflammatory (CB2 agonist), Antifungal
Tannins	Condensed & hydrolysable tannins	Root, Bark	Haemostatic, Astringent, Antimicrobial
Saponins	Steroidal saponins	Root, Seed	Adjuvant activity, Antihyperlipidaemic

5. Documented and Putative Pharmacological Activities

5.1 Antioxidant Activity

Antioxidant activity is the most consistently documented pharmacological property across Rhapis and related palm species. Multiple extraction solvents (methanol, ethanol, ethyl acetate, aqueous) from R. excelsa leaves and roots have shown significant free radical scavenging activity in the DPPH (2,2-diphenyl-1-picrylhydrazyl) assay and the ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) radical cation decolourisation assay. The phenolic-rich fractions consistently exhibit the highest antioxidant potency, with IC50 values in the range of 15–80 micrograms/mL in published studies on related Arecaceae species.

The antioxidant activity of quercetin, kaempferol, and chlorogenic acid — identified or inferred in R. excelsa — is well-established. These compounds donate hydrogen atoms to neutralise reactive oxygen species (ROS), chelate pro-oxidant metal ions (Fe^{2+}, Cu^{2+}), and upregulate endogenous antioxidant enzymes (SOD, CAT, GPx) through activation of the Nrf2/Keap1 signalling pathway. Pharmaceutical applications include formulation of antioxidant dietary supplements, cosmeceuticals targeting oxidative stress-related skin ageing, and potential adjuvant therapy in oncology.

5.2 Anti-inflammatory Activity

Ethanolic and aqueous extracts of Rhapis species have demonstrated inhibition of pro-inflammatory mediators in both in vitro and (for related species) in vivo models. Key mechanisms include:

- Inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzyme activity by flavonoids and ursolic acid, reducing prostaglandin E2 and leukotriene B4 synthesis.
- Suppression of NF-kB pathway activation, reducing transcription of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in LPS-stimulated macrophage models (RAW 264.7 cell line).
- Beta-caryophyllene-mediated selective CB2 cannabinoid receptor agonism, activating endocannabinoid anti-inflammatory pathways without psychotropic effects.
- Inhibition of nitric oxide (NO) production via downregulation of inducible nitric oxide synthase (iNOS) in activated macrophages.

These findings support potential development of R. excelsa extracts as botanical anti-inflammatory agents for nutraceutical formulations addressing chronic inflammatory conditions such as osteoarthritis, inflammatory bowel disease, and metabolic syndrome.

5.3 Antimicrobial Activity

Leaf and root extracts of Rhapis species have demonstrated in vitro antimicrobial activity against a range of clinically relevant pathogens. The documented antimicrobial spectrum, based on agar disc diffusion and minimum inhibitory concentration (MIC) assays, includes activity against:

Organism	Type	Sensitivity	Proposed Active Constituent
Staphylococcus aureus (MRSA)	Gram+ve bacterium	Moderate–High	Flavonoids, Tannins, Lauric acid
Bacillus subtilis	Gram+ve bacterium	High	Phenolic acids, Tannins
Escherichia coli	Gram-ve bacterium	Low–Moderate	Quercetin, Gallic acid
Pseudomonas aeruginosa	Gram-ve bacterium	Low	Terpenes
Candida albicans	Yeast / fungus	Moderate	Phenolics, Fatty acids
Aspergillus niger	Mould / fungus	Moderate	Terpenes, Flavonoids

The preferential activity against Gram-positive organisms is consistent with the hydrophobic nature of flavonoids and tannins, which disrupt peptidoglycan-rich cell walls. The potential activity against MRSA strains is of particular clinical interest given the global challenge of antibiotic resistance. MIC values for flavonoid-rich fractions in comparable Arecaceae studies range from 0.5 to 4 mg/mL, which while modest, warrants further investigation for synergistic formulations with conventional antibiotics.

5.4 Antidiabetic Activity

Several phytoconstituents identified in or inferred for Rhapis excelsa are relevant to blood glucose management. Chlorogenic acid, one of the most well-studied plant phenolics, is a potent inhibitor of glucose-6-phosphate translocase (G6PT), reducing hepatic glucose output — a mechanism exploited in type 2 diabetes management. Quercetin has been shown to stimulate insulin secretion from pancreatic beta-cells and improve insulin sensitivity through activation of the PI3K/Akt pathway. Luteolin inhibits alpha-glucosidase and alpha-amylase enzymes, slowing carbohydrate digestion and post-prandial glucose rise.

In vitro alpha-glucosidase inhibition assays with phenolic-rich fractions from related palms have yielded IC50 values comparable to or lower than acarbose (the reference drug), suggesting pharmaceutical formulation potential. In vivo antidiabetic studies on Rhapis excelsa specifically remain to be conducted and represent a significant gap in the literature.

5.5 Hepatoprotective Activity

Ursolic acid, oleanolic acid, and quercetin — documented or inferred in R. excelsa — have well-established hepatoprotective mechanisms. In carbon tetrachloride (CCl_4) and paracetamol (acetaminophen)-induced hepatotoxicity models, these compounds reduce serum liver enzyme levels (ALT, AST, ALP), improve antioxidant status in hepatic tissue (GSH levels), and attenuate histopathological changes in hepatocytes. Mechanisms include scavenging of free radicals generated during hepatic drug metabolism, upregulation of hepatic glutathione S-transferase (GST) activity, and anti-apoptotic effects on hepatocytes via Bcl-2/Bax pathway modulation.

Hepatoprotective herbal formulations represent a major segment of the global complementary medicine market. Standardised R. excelsa extracts enriched for ursolic acid and quercetin content may have potential in this therapeutic area, pending in vivo and clinical validation.

5.6 Immunomodulatory Activity

Polysaccharide fractions from Arecaceae stem and seed tissues have demonstrated immunostimulatory activity in RAW 264.7 macrophage cultures, increasing phagocytic index and stimulating NO and cytokine (TNF-alpha, IL-6) production. While this seemingly contradicts anti-inflammatory findings, the distinction lies in context: immunostimulation is relevant in immunosuppressed states (chemotherapy patients, chronic infections), while anti-inflammatory activity is relevant in hyperinflammatory conditions. This dual, context-dependent immunomodulation — a feature shared with several well-characterised medicinal polysaccharides such as those from Ganoderma lucidum — is a pharmacologically important property worthy of systematic investigation in R. excelsa.

5.7 Anticancer / Cytotoxic Activity

Betulinic acid and ursolic acid — triterpenoids inferred from Arecaceae phytochemical data — have demonstrated cytotoxic activity against multiple human cancer cell lines including melanoma (SK-MEL-28), cervical carcinoma (HeLa), hepatocellular carcinoma (HepG2), and breast adenocarcinoma (MCF-7). Quercetin and luteolin exert antiproliferative effects through induction of G2/M cell cycle arrest and caspase-mediated apoptosis. Kaempferol has been shown to inhibit tumour angiogenesis by downregulating VEGF expression.

These cytotoxic activities have been characterised in model systems for related Arecaceae genera. Targeted cytotoxicity studies on R. excelsa extracts and isolated fractions against a panel of human cancer cell lines represent a high-priority area for future research. Such studies would be aided by the development of standardised extraction protocols and reference phytochemical markers for R. excelsa.

5.8 Wound Healing Activity

The traditional use of R. excelsa stem fibre and leaf preparations for wound management is supported by the pharmacology of their likely constituents. Tannins (astringent, pro-haemostatic), flavonoids (anti-inflammatory, antioxidant, collagen synthesis promotion), and polysaccharides (water retention, wound bed hydration) all contribute to wound healing efficacy. Additionally, the physical properties of R. excelsa fibres — high tensile strength, biocompatibility, capacity for surface functionalisation — make them candidates for development as biodegradable wound dressing substrates or tissue engineering scaffolds. Preliminary studies on Arecaceae fibre-based wound matrices have shown favourable cytocompatibility in keratinocyte and fibroblast cultures.

5.9 Phytoremediation and Respiratory Health

The well-documented capacity of R. excelsa to remove indoor air pollutants — including formaldehyde, ammonia, and xylene — from enclosed environments (Wolverton et al., 1989; subsequent replication studies) has indirect but significant respiratory health relevance. Prolonged indoor exposure to formaldehyde (a Group 1 IARC carcinogen) and ammonia (a respiratory irritant) is linked to increased risk of asthma, rhinitis, nasopharyngeal carcinoma, and other respiratory and mucosal pathologies. The integration of R. excelsa into healthcare facility interiors, hospital wards, and pharmaceutical laboratory environments may therefore contribute meaningfully to occupational health outcomes — an under-explored area of clinical application.

6. Pharmacognostic Standardisation and Quality Control Parameters

For pharmaceutical development of Rhapis excelsa-based preparations, rigorous standardisation is essential. The following parameters are recommended based on WHO guidelines for herbal drug quality, adapted to R. excelsa:

6.1 Physico-Chemical Standards (Leaf Drug)

Parameter	Method	Expected / Target Value
Foreign organic matter	IP/WHO visual inspection	Not more than 2%
Loss on drying (moisture)	Gravimetric, 105°C, 5 h	Not more than 10% w/w
Total ash	Incineration at 550°C	Not more than 8% w/w
Acid-insoluble ash	Treatment with dil. HCl	Not more than 2% w/w
Water-soluble extractive	Cold maceration, H2O, 6 h	Not less than 15% w/w
Ethanol-soluble extractive (70%)	Cold maceration, 6 h	Not less than 10% w/w
Total phenolic content	Folin-Ciocalteu; GAE	To be determined (TBD)
Total flavonoid content	AlCl3 colorimetric; QE	To be determined (TBD)
Heavy metals	ICP-MS	Pb < 5 ppm; Cd < 0.3 ppm; As < 1 ppm; Hg < 0.5 ppm
Microbial contamination	Aerobic plate count	Total aerobic bacteria < 10^5 CFU/g; Absence of E. coli, Salmonella
Pesticide residues	GC-MS/MS multi-residue	Within EU/WHO MRL limits

6.2 Marker Compound Identification

Thin Layer Chromatography (TLC) on silica gel GF254, with chloroform:methanol:formic acid (8:2:0.1) mobile phase, reveals characteristic flavonoid spots under UV 366 nm after spraying with Natural Products Reagent A (NP-PEG). High-Performance Liquid Chromatography (HPLC) with UV detection at 254 nm and 370 nm, using a C18 reverse-phase column and acetonitrile-water gradient (with 0.1% formic acid), is recommended for quantification of quercetin, kaempferol, and chlorogenic acid as primary marker compounds. An HPLC-MS method for confirmation of identity and detection of adulterants should be developed as part of any official monograph preparation.

6.3 Fingerprint Chromatography

A standardised HPLC fingerprint of R. excelsa leaf ethanolic extract should be established, identifying 8–12 major chromatographic peaks for use in authentication and batch-to-batch consistency verification. UPLC-QTOF-MS metabolomics profiling would enable comprehensive characterisation of the chemical space and support the development of a chemometric authentication model to distinguish R. excelsa from potential adulterant species (particularly R. humilis and R. multifida).

7. Toxicological Profile and Safety Considerations

7.1 General Safety

Rhapis excelsa is classified as non-toxic to humans, dogs, cats, and horses by the American Society for the Prevention of Cruelty to Animals (ASPCA), and no clinically significant human toxicity events have been documented in the literature. The plant does not appear on any major regulatory agency lists of herbs of concern. This favourable safety profile — consistent with its centuries-long use as an ornamental and incidental medicinal plant — is an asset for pharmaceutical development.

7.2 Calcium Oxalate Content

Like many Arecaceae species, R. excelsa contains raphide crystals of calcium oxalate in leaf idioblasts. When raw plant material is consumed or applied to mucous membranes, calcium oxalate raphides can cause mechanical irritation, burning sensation, and oedema of the oral mucosa and throat (a condition known as raphide dermatitis). This is pharmacognostically relevant: pharmaceutical preparations intended for oral use should employ extraction protocols that eliminate or minimise calcium oxalate content, and raw material ingestion should be discouraged. Heating during extraction significantly reduces raphide-related irritation.

7.3 Acute Toxicity

Formal acute toxicity studies (LD50 determination) on R. excelsa extracts have not been published. Based on analogy with structurally similar Arecaceae extracts subjected to OECD Test Guideline 423 (Acute Oral Toxicity), standardised ethanolic leaf extracts are expected to be in the 'unclassified' or Category 5 (LD50 > 2000 mg/kg body weight) of the GHS classification. Formal in vivo acute toxicity studies are required before clinical development of any pharmaceutical preparation.

7.4 Genotoxicity and Mutagenicity

No genotoxicity data are available specifically for R. excelsa. The Ames test (Salmonella typhimurium reverse mutation assay) and chromosomal aberration test should be conducted as part of any preclinical safety package. The presence of flavonoids at high concentrations raises theoretical concern, as some flavonoids can act as pro-oxidants and topoisomerase II inhibitors; however, at pharmacological doses achievable from standardised plant extracts, these effects are generally outweighed by protective activities.

7.5 Drug-Herb Interactions

Given the inhibitory effects of quercetin on CYP3A4, CYP2C9, and P-glycoprotein drug transporters documented in vitro, preparations highly enriched in quercetin could theoretically alter the pharmacokinetics of co-administered drugs metabolised by these enzymes (e.g., statins, warfarin, cyclosporine, certain antiretrovirals). This potential interaction should be addressed in clinical guidance accompanying any pharmaceutical-grade product, and appropriate studies conducted where co-administration with critical-dose drugs is likely.

8. Potential Pharmaceutical and Nutraceutical Applications

8.1 Standardised Herbal Extract Products

The most immediately realisable pharmaceutical application of R. excelsa is the development of standardised dried extract powders, concentrated liquid extracts, or tinctures enriched for total phenolics, flavonoids, or specific marker compounds (quercetin, chlorogenic acid). These could be formulated as dietary supplement capsules, tablets, or granules for the antioxidant, anti-inflammatory, or hepatoprotective supplement market, following registration frameworks under AYUSH (India), THMPD (EU Traditional Herbal Medicinal Products Directive), or dietary supplement regulations (DSHEA, USA).

8.2 Cosmeceutical Formulations

The antioxidant, anti-inflammatory, and potentially collagen-synthesis-promoting activities of R. excelsa flavonoid-rich extracts make them candidates for cosmeceutical application in anti-ageing skincare. Formulations might include serum, emulsion, or gel preparations incorporating standardised R. excelsa extract at 0.5–5% w/w, targeting oxidative stress-related skin ageing, hyperpigmentation (via inhibition of tyrosinase by quercetin and kaempferol), and UV-induced erythema. Stability studies, preservative compatibility assessment, and patch testing are required for cosmeceutical product development.

8.3 Wound Dressing Biomaterials

The strong, biodegradable fibres of R. excelsa leaf sheaths present an opportunity for development of eco-friendly wound dressing substrates. Microcrystalline cellulose (MCC) and nanocellulose derived from palm fibres have been investigated as pharmaceutical excipients, and the favourable tensile properties of Rhapis fibres — which are comparable to those of other commercially exploited palm fibres (coconut coir, palmyra) — support further investigation. A bioactive wound dressing combining R. excelsa fibre scaffold with an impregnated flavonoid-rich extract could integrate the mechanical function of the fibre with the wound-healing pharmacology of the extract.

8.4 Drug Delivery Excipient

Palm seed polysaccharides (mannans and glucomannans) from Arecaceae species have been investigated as natural polymer excipients for matrix tablet formulation, hydrogel preparation, and microparticle/nanoparticle carriers. Their mucoadhesive properties make them particularly relevant for buccal, nasal, and gastrointestinal drug delivery applications. R. excelsa seed polysaccharide characterisation — including molecular weight distribution, viscosity profiles, and gelation behaviour — would be necessary to assess their excipient utility.

8.5 Phytoremediation in Pharmaceutical Manufacturing

Indoor air quality in pharmaceutical manufacturing facilities, analytical laboratories, and hospital pharmacies is regulated under GMP and healthcare standards. The documented capacity of R. excelsa to reduce formaldehyde, ammonia, and aromatic VOC levels in enclosed spaces — compounds commonly present in pharmaceutical manufacturing environments as process solvents and cleaning agent residues — suggests a practical biophilic air management application. Integration of Lady Palm specimens into cleanroom anteroom plantscapes could contribute to background air quality alongside mechanical HVAC filtration.

9. Conclusion

Rhapis excelsa (Lady Palm) presents a compelling, if incompletely characterised, phytochemical and pharmacological profile of genuine pharmaceutical relevance. Its phytochemical composition — dominated by flavonoids, phenolic acids, phytosterols, triterpenoids, and polysaccharides — underpins a spectrum of biological activities including antioxidant, anti-inflammatory, antimicrobial, antidiabetic, hepatoprotective, wound-healing, and immunomodulatory effects, all consistent with its traditional medicinal applications across East and Southeast Asian medicine systems.

The plant's exceptional indoor adaptability, slow growth, wide availability as a cultivated ornamental, favourable safety profile (non-toxic to humans and companion animals), and the demonstrated phytoremediation activity relevant to respiratory health position it as a uniquely versatile candidate for pharmaceutical, nutraceutical, and cosmeceutical development. The major limiting factor at present is the paucity of targeted pharmacological and clinical research directly on R. excelsa. Bridging this evidence gap through systematic phytochemical and pharmacological investigation is the foremost priority for realising the plant's pharmaceutical potential.

This review is intended to serve as a foundational reference for pharmacy students, pharmacognosy researchers, and natural product drug discovery scientists, providing a consolidated evidence base and a structured research agenda for Rhapis excelsa as a medicinal plant of emerging pharmaceutical significance.

References

1. Wolverton BC, Johnson A, Bounds K. Interior Landscape Plants for Indoor Air Pollution Abatement. NASA Technical Report NASA/TM-1989-194109. 1989.

2. Dransfield J, Uhl NW, Asmussen CB, Baker WJ, Harley MM, Lewis CE. Genera Palmarum: The Evolution and Classification of Palms. Kew Publishing; 2008.

3. WHO. WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants. Geneva: World Health Organisation; 2003.

4. WHO. Quality Control Methods for Herbal Materials (Updated Edition). Geneva: World Health Organisation; 2011.

5. Kim KJ, Jeong MI, Lee DW, et al. Variation in formaldehyde removal efficiency among indoor plant species. HortScience. 2010;45(10):1489-1495.

6. Baliga MS, Shivashankara AR, Haniadka R, et al. Phytochemistry, nutritional and pharmacological properties of Arecanut (Areca catechu L.): A review. Food Research International. 2011;44(7):1812-1822.

7. Chandrasekaran M, Senthilkumar A, Venkatesalu V. Antibacterial and antifungal efficacy of fatty acid methyl esters from the leaves of Sesuvium portulacastrum. Eur Rev Med Pharmacol Sci. 2011;15:775-780.

8. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr. 2000;130(8 Suppl):2073S-2085S.

9. Hodel DR. Chamaedorea Palms: The Species and Their Cultivation. International Palm Society; 1992.

10. Agra MF, Freitas PF, Barbosa-Filho JM. Synopsis of the plants known as medicinal and poisonous in northeast of Brazil. Braz J Pharmacogn. 2007;17(1):114-140.

11. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673-751.

12. Bishayee A, Mbimba T, Thoppil RJ, et al. Anthocyanin-rich black currant (Ribes nigrum L.) extract affords chemoprevention against diethylnitrosamine-induced hepatocellular carcinogenesis in rats. J Nutr Biochem. 2011;22(11):1035-1046.

13. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3(10):768-780.

14. ASPCA Animal Poison Control Center. Toxic and Non-Toxic Plant List. 2024. Available at: www.aspca.org

15. European Medicines Agency (EMA). Guideline on Specifications: Test Procedures and Acceptance Criteria for Herbal Substances, Herbal Preparations and Herbal Medicinal Products/Traditional Herbal Medicinal Products. EMA/CPMP/QWP/2820/00 Rev.3. 2016.